DEUTERATED DERIVATIVES OF RUXOLITINIB
The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
1 - 9 . (canceled)
10 . A compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein each position in the compound designated specifically as deuterium has at least 90% incorporation of deuterium.
11 . The compound of claim 10 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.
12 . The compound of claim 10 , wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium.
13 . The compound of claim 12 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.
14 . The compound of claim 10 , wherein each position designated specifically as deuterium has at least 97% incorporation of deuterium.
15 . The compound of claim 14 , wherein the pharmaceutically acceptable salt of the compound is the phosphate salt.
16 . A pharmaceutical composition comprising the compound of claim 10 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17 . The pharmaceutical composition of claim 16 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.
18 . A pharmaceutical composition comprising the compound of claim 12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
19 . The method of claim 18 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.
20 . A pharmaceutical composition comprising the compound of claim 14 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
21 . The method of claim 20 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.
22 . A method of inhibiting the activity of one or more of JAK1 or JAK2, in a cell, comprising contacting the cell with a compound of claim 10 or a pharmaceutically acceptable salt thereof.
23 . The method of claim 22 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.
24 . A method of inhibiting the activity of one or more of JAK1 or JAK2, in a cell, comprising contacting the cell with a compound of claim 12 or a pharmaceutically acceptable salt thereof.
25 . The method of claim 24 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.
26 . A method of inhibiting the activity of one or more of JAK1 or JAK2, in a cell, comprising contacting the cell with a compound of claim 14 or a pharmaceutically acceptable salt thereof.
27 . The method of claim 26 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.
28 . A method of treating myelofibrosis, pancreatic cancer, prostate cancer, breast cancer, leukemia, non-Hodgkin's lymphoma, multiple myeloma, psoriasis, or a combination thereof in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein each position in the compound designated specifically as deuterium has at least 90% incorporation of deuterium.
29 . The method of claim 28 , wherein the pharmaceutically acceptable salt of the compound is the phosphate salt.